(4S)-4-{[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}butanoyl]-L-proline | 1321614-52-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4S)-4-{[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}butanoyl]-L-proline
• 英文别名: (2S,4S)-4-[[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]amino]-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]butanoyl]pyrrolidine-2-carboxylic acid
• CAS: 1321614-52-1
• 化学式: C₃₁H₃₉F₃N₄O₆
• 分子量: 620.669
• InChiKey: MHPCLJLBYLDZRH-PYVLESRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  44
• 可旋转键数：
  16
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  151
• 氢给体数：
  4
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  (4S)-4-{[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}butanoyl]-L-proline 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (4S)-4-{[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}butanoyl]-L-proline
  参考文献：
  名称：

  Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome

  摘要：

  Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.04.036
• 作为产物：
  描述：

  Boc-(R)-3-氨基-4-(2,4,5-三氟苯基)丁酸 在 palladium on activated charcoal 、 甲酸铵 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氟乙酸 作用下， 以 甲醇 、 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 、 N,N-二甲基甲酰胺 为溶剂， 生成 (4S)-4-{[(3R)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}butanoyl]-L-proline
  参考文献：
  名称：

  Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome

  摘要：

  Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.04.036

文献信息

• Approaches towards the development of chimeric DPP4/ACE inhibitors for treating metabolic syndrome
  作者：Jitendra A. Sattigeri、Sachin Sethi、Joseph A. Davis、Shahadat Ahmed、Geeta V. Rayasam、Balasaheb G. Jadhav、Satya M. Chilla、Dhrubajyoti Datta、A. Gadhave、Vamshi K. Tulasi、Tarun Jain、Sreedhara Voleti、Biju Benjamin、Sunitha Udupa、Garima Jain、Yogender Singh、Kona Srinivas、Vinay S. Bansal、Abhijit Ray、Pradip K. Bhatnagar、Ian A. Cliffe

  DOI：10.1016/j.bmcl.2017.04.036

  日期：2017.6

  Designing drug candidates exhibiting polypharmacology is one of the strategies adopted by medicinal chemists to address multifactorial diseases. Metabolic disease is one such multifactorial disorder characterized by hyperglycaemia, hypertension and dyslipidaemia among others. In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE. (C) 2017 Elsevier Ltd. All rights reserved.